| Code | CSB-RA011651MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody targets IL2RG (Interleukin-2 Receptor Gamma chain), also known as the common gamma chain (γc), a critical component shared by multiple cytokine receptors including those for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. IL2RG plays an essential role in lymphocyte development, differentiation, and survival by mediating signal transduction through the JAK-STAT pathway. Mutations in the IL2RG gene cause X-linked severe combined immunodeficiency (X-SCID), characterized by profound T and NK cell deficiency. Additionally, IL2RG is implicated in various immune disorders, autoimmune conditions, and hematological malignancies, making it a valuable target for immunological research.
This biosimilar antibody is developed with reference to patent US20200247894A1, which describes therapeutic antibodies targeting IL2RG for potential immunomodulatory applications. It serves as a valuable research tool for investigating cytokine receptor signaling pathways, studying immune cell development and function, and exploring the molecular mechanisms underlying primary immunodeficiencies and immune-related diseases. The antibody enables researchers to examine IL2RG expression patterns and functional roles across various experimental models.
There are currently no reviews for this product.